Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

By BiotechDaily International staff writers
Posted on 20 Apr 2014
Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells.

Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating MCF-10F human normal breast epithelial cells with a high dose of estradiol. The model system consisted of four distinct cell lines which demonstrated a progressive neoplastic transformation: MCF-10F, normal stage; trMCF, transformed MCF-10F; bsMCF, invasive stage; and caMCF, tumorigenic stage. In three-dimensional cultures, MCF-10F cells formed tubules resembling the structures in the normal mammary gland. After treatment with estradiol, these cells formed tubules and spherical masses which were indicative of transformation.

In the current study the investigators evaluated the effect of all trans-retinoic acid (ATRA) at different stages of neoplastic transformation. Retinoids have been used as potential chemotherapeutic or chemopreventive agents because of their differentiative, antiproliferative, proapoptotic, and antioxidant properties.

Cells that only formed spherical masses in collagen were isolated (trMCF clone 11) and treated with ATRA. After treatment with a concentration of one micromolar ATRA, the trMCF clone 11 cells showed tubules in collagen. Gene expression studies showed that 207 genes upregulated in transformed trMCF clone 11 cells were downregulated after one micromolar ATRA treatment to levels comparable to those found in the normal breast epithelial cells MCF-10F. Furthermore, 236 genes that were downregulated in trMCF clone 11 were upregulated after one micromolar ATRA treatment to similar levels shown in normal epithelial cells. These 443 genes defined a signature of the ATRA reprogramming effect.

Results published in the March 21, 2014, edition of the International Journal of Oncology showed that one micromolar ATRA was able to re-differentiate transformed cells at early stages of the neoplastic process and antagonistically regulate breast cancer associated genes. On the other hand, the invasive and tumorigenic cells did not show any changes in morphology after ATRA treatment.

“It looks like retinoic acid exerts effects on cancer cells in part via the modulation of the epigenome,” said senior author Dr. Sandra V. Fernandez, assistant research professor of medical oncology at Thomas Jefferson University. “We were able to see this effect of retinoic acid because we were looking at four distinct stages of breast cancer. It will be interesting to see if these results can be applied to patients.”

Related Links:

Thomas Jefferson University



Channels

Genomics/Proteomics

view channel
Image: The non-active drug is activated when it becomes localized at a site with excessive inflammation (Photo courtesy of Ben-Gurion University of the Negev).

Chimeric Drug Reduces Local Inflammation Without Causing General Immune Suppression

A novel anti-inflammatory drug is based on a chimeric molecule that avoids general immune suppression by being non-active when injected but is converted into an activate agent by leukocytes concentrated... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.